CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Atrandi Biosciences›
Analysis
Atrandi Biosciences

Atrandi Biosciences

Atrandi Biosciences builds instruments and kits for high-throughput single-cell analysis using semi-permeable capsules and droplet microfluidics.

Operating headquarters
Vilnius, LT🇱🇹
Founded
2016
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Contents

  1. 01Market Outlook
  2. 02Competitive Strengths
  3. 03Competitive Risks
  1. 01Market Outlook
  2. 02Competitive Strengths
  3. 03Competitive Risks

Market Outlook

Atrandi reports use by more than 200 research groups and deployment of more than 150 instruments. Its products address single-cell multiomics, microbial genomics, and functional screening, with separate platforms for capsule generation, flexible microfluidics, and droplet sorting.

The February 2025 financing release states an intent to expand in the United States, and a September 2026 company article announces eight distribution partners across Asia-Pacific. Those are concrete expansion signals; the available sources do not establish a quantified market size or forecast future sales.

Competitive Advantages

Atrandi's semi-permeable capsules retain cells and long nucleic acids while letting buffers, enzymes, and other small reagents pass through. This supports successive reactions on the same isolated cell, addressing a limitation the company identifies in closed droplet workflows.

The current portfolio covers push-button capsule generation with Flux, configurable droplet and capsule work on Onyx, and fluorescence-activated screening with Styx. The company also sells application kits and consumables, giving research labs an instrument-and-reagent path for both standardized and custom workflows.

Competitive Disadvantages

The company's DNA and RNA co-sequencing page presents targeted DNA plus RNA profiling as early access while two broader protocols remain in development. Researchers needing those broader assays as released workflows therefore cannot treat every described application as generally available today.

Onyx emphasizes custom parameter control, chip choice, and assay optimization, which may demand more method development from a laboratory than a fixed assay. Flux offers a simpler capsule-generation route, but the catalog still ties many workflows to dedicated instruments and matching kits or consumables. These are adoption considerations inferred from the product pages, not measured customer outcomes.